The use of genetic materials for treatment is a relatively simple concept which, if successful, could revolutionise the management of both inherited and acquired disease. The aim is to modify production of a specific protein either through upregulation by introducing the DNA of interest, or downregulation through the use of antisense oligonucleotides. Such modification could be for long term correction of an inherited genetic defect such as cystic fibrosis or ot,-antitrypsin deficiency, on the one hand, or an acquired defect such as cancer on the other. Alternatively, short term modification of protein production could be used to alter inflammation in conditions such as asthma and oxidant-mediated lung injury. Although the concepts are simple, the technology is complex and poorly understood, and it will be some time before gene therapy is routinely available in clinical practice. This editorial outlines the technology of gene transfer and reviews progress towards therapy for the three lung conditions with approved gene therapy protocols, namely cystic fibrosis, ocl-antitrypsin deficiency, and lung cancer.
Gene transfer techniques Gene transfer requires two principal components -the cDNA of interest linked to an appropriate promoter, and a gene transfer agent to facilitate entry into the cell. Most current studies use "ubiquitous" promoters such as SV40, CMV and RSV which are derived from eukaryotic viruses and, in theory, are active in any nucleated cell. Lung specific promoters such as SP-C (surfactant protein C) and CC 10 (Clara cell) are also being investigated.' There has, to date, been relatively little work done to define the relative advantages of the different promoters. It is likely, however, that cell specificity will prove to be valuable as it will limit gene expression to a desired cell population and may also be easier to control. Based on these studies one human gene therapy protocol has been submitted to the regulatory authorities in the USA. This will first assess whether topical application of liposome-AAT complexes into the nasal epithelium of subjects with oxl-antitrypsin deficiency results in detectable mRNA and protein, and whether any histological changes are seen as a result of gene transfer. Subsequently, the study aims to deliver the complex into the lower airways of subjects scheduled for elective pneumonectomy. Three days before surgery the complex will be instilled bronchoscopically and the site of exposure marked with a dye. At the time of surgery the transfected area will be lavaged for assessment of ocl-antitrypsin levels and the specimen examined for mRNA and protein. A second strategy is to upregulate the production of tumour suppressor genes. p53 is a protein involved in DNA repair and synthesis, and mutations in this gene have been shown to be an independent poor prognostic factor in lung 
